DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1209087
Title:
NY-ESO-1 Specific TCR-Engineered T Cell Immunotherapy for Triple Negative Breast Cancer
Report Date:
2023-07-01
Abstract:
The purpose of this award will be to address the overarching challenge of eliminating mortality associated with metastatic breast cancer, specifically, the subtype, TNBC. We hypothesize that treatment of TNBC patients with NY-ESO-1 TCR-transduced T cells is safe and will result in tumor regression and clinical benefits. We further hypothesize that maximal therapeutic immunity could be achieved by improving T cell persistence and trafficking of A2-ESO-1 TCR engineered T cells, as well as critical help and cytotopic function of DP4-ESO-1 TCR-transduced CD4+ T cells. Importantly, such an antitumor immunity could be further amplified in vivo by blocking immune suppression.
Document Type:
Conference:
Journal:
Pages:
59
File Size:
3.45MB
WW81XWH-16-1-0418
(WW81XWH1610418);
Contracts:
Grants:
Distribution Statement:
Approved For Public Release
